Next Article in Journal
Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
Previous Article in Journal
Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma
Previous Article in Special Issue
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
Open AccessReview

Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation

Department of Breast Surgery, Royal Marsden NHS Foundation Trust, Fulham Road, London SW36JJ, UK
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 140; https://doi.org/10.3390/cancers12010140
Received: 27 November 2019 / Revised: 17 December 2019 / Accepted: 20 December 2019 / Published: 6 January 2020
(This article belongs to the Special Issue Treatment Strategies and Survival Outcomes in Breast Cancer)
The uptake of contralateral prophylactic mastectomy is rising with increasing trends that are possibly highest in the USA. Whilst its role is generally accepted in carriers of recognized high-risk predisposition genes such as BRCA1 and BRCA2 when the affected individual is premenopausal, controversy surrounds the benefit in less understood risk-profile clinical scenarios. This comprehensive review explores the current evidence underpinning the role of contralateral prophylactic mastectomy and its impact on contralateral breast cancer risk and survival in three distinct at-risk groups affected by unilateral breast cancer: known genetic carriers, those with strong familial risk but no demonstrable genetic mutation and women who are of young age at presentation. The review supports the role of contralateral prophylactic mastectomy in “high risk” groups where the evidence suggests a reduction in contralateral breast cancer risk. However, this benefit is less evident in women who are just young at presentation or those who have strong family history but no demonstrable genetic mutation. A multidisciplinary and personalized approach to support individuals in a shared-decision making process is recommended. View Full-Text
Keywords: contralateral prophylactic mastectomy; contralateral breast cancer; BRCA; CHEK2; PALB2; ATM; mutation carriers; family history; survival contralateral prophylactic mastectomy; contralateral breast cancer; BRCA; CHEK2; PALB2; ATM; mutation carriers; family history; survival
MDPI and ACS Style

Teoh, V.; Tasoulis, M.-K.; Gui, G. Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Genetic Carriers, Have a Strong Family History or Are just Young at Presentation. Cancers 2020, 12, 140.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop